Drug Profile


Alternative Names: Albenza; Bilutac®; Escazole®; Eskazole®; Proftril®; SKF 62979; Zentel®

Latest Information Update: 07 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; PharmAust
  • Class Anthelmintics; Benzimidazoles; Carbamates; Small molecules
  • Mechanism of Action Tubulin inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Helminthiasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Helminthiasis
  • Phase I/II Ascites

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Helminthiasis(In volunteers) in China (PO, Tablet)
  • 31 May 2013 Phase-I/II clinical trials in Ascites in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top